Rebecca A. DeStefanis

Rebecca A. DeStefanis

Auto-generated profile, based on publicly available information

Rebecca A. DeStefanis

McArdle Laboratory for Cancer Research, Department of Oncology, University of Wisconsin, Madison, Wisconsin

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2025 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
RDRebecca A. DeStefanis
Rebecca A. DeStefanis
ASAlexa E. Schmitz
Alexa E. Schmitz
A(Alyssa Steimle (DeZeeuw)
Alyssa Steimle (DeZeeuw)
SPSusan N. Payne
Susan N. Payne
GSGioia C. Sha
Gioia C. Sha
DDDustin Deming
Dustin Deming
Targeting PIK3CA-mutant colorectal cancers with precision medicine strategies is of great clinical interest. However, resistance to single-agent PI3K pathway inhibitors has been observed across multiple clinical trials, necessitating the identification of combination therapies that overcome or prevent resistance to precision medicine strategies. Previously, our group identified that inhibition of mTORC1/2 is necessary to induce a response in PIK3CA-mutant colorectal cancers. The PI3K/mTORC1/2 inhibitor copanlisib has demonstrated some clinical activity in PIK3CA-mutant solid tumors as part of the NCI-MATCH trial. In this study, we evaluate potential combination therapies that could enhance the efficacy of copanlisib and other similar inhibitors in PIK3CA-mutant colorectal cancers. Using a novel high-throughput drug screen method in Apc- and Pik3ca-mutant mouse-derived cancer organoids, we identify navitoclax, a BCL-2 family inhibitor, as a drug that could potentially enhance the response to copanlisib. Across multiple in vitro and in vivo colorectal cancer models, navitoclax enhanced PI3K/mTOR inhibition (copanlisib, sapanisertib, and dactolisib) and induced apoptosis. Furthermore, we examine these combination therapies across a panel of patient-derived cancer organoids with a range of mutation profiles. These studies indicate that KRAS mutations could confer resistance. Furthermore, we identify BCL-xL as the major BCL-2 family target important for the response to this combination in this setting. This provides a strong rationale for mTORC1/2 and BCL-2 family inhibition as a potential treatment strategy for PIK3CA-mutant colorectal cancers.

2 December 2025
Verified
Other
Open access
RDRebecca A. DeStefanis
Rebecca A. DeStefanis
ASAlexa E. Schmitz
Alexa E. Schmitz
A(Alyssa Steimle (DeZeeuw)
Alyssa Steimle (DeZeeuw)
SPSusan N. Payne
Susan N. Payne
GSGioia C. Sha
Gioia C. Sha
DDDustin Deming
Dustin Deming
Supplementary Data of Sequencing Results from PDCOs.

2 December 2025
Verified
Other
Open access
RDRebecca A. DeStefanis
Rebecca A. DeStefanis
ASAlexa E. Schmitz
Alexa E. Schmitz
A(Alyssa Steimle (DeZeeuw)
Alyssa Steimle (DeZeeuw)
SPSusan N. Payne
Susan N. Payne
GSGioia C. Sha
Gioia C. Sha
DDDustin Deming
Dustin Deming
Supplementary Figure 3. Combination of copanlisib and navitoclax enhances apoptosis in multiple models of CRC.

2 December 2025
Verified
Other
Open access
RDRebecca A. DeStefanis
Rebecca A. DeStefanis
ASAlexa E. Schmitz
Alexa E. Schmitz
A(Alyssa Steimle (DeZeeuw)
Alyssa Steimle (DeZeeuw)
SPSusan N. Payne
Susan N. Payne
GSGioia C. Sha
Gioia C. Sha
DDDustin Deming
Dustin Deming
Supplementary Figure 4. Combination of copanlisib and navitoclax does not significantly alter the RAS/RAF pathway.

2 December 2025
Verified
Other
Open access
RDRebecca A. DeStefanis
Rebecca A. DeStefanis
ASAlexa E. Schmitz
Alexa E. Schmitz
A(Alyssa Steimle (DeZeeuw)
Alyssa Steimle (DeZeeuw)
SPSusan N. Payne
Susan N. Payne
GSGioia C. Sha
Gioia C. Sha
DDDustin Deming
Dustin Deming
Supplementary Figure 2. Navitoclax enhances the responses of copanlisib in murine and human CRC lines.

2 December 2025
Verified
Other
Open access
RDRebecca A. DeStefanis
Rebecca A. DeStefanis
ASAlexa E. Schmitz
Alexa E. Schmitz
A(Alyssa Steimle (DeZeeuw)
Alyssa Steimle (DeZeeuw)
SPSusan N. Payne
Susan N. Payne
GSGioia C. Sha
Gioia C. Sha
DDDustin Deming
Dustin Deming
Targeting PIK3CA-mutant colorectal cancers with precision medicine strategies is of great clinical interest. However, resistance to single-agent PI3K pathway inhibitors has been observed across multiple clinical trials, necessitating the identification of combination therapies that overcome or prevent resistance to precision medicine strategies. Previously, our group identified that inhibition of mTORC1/2 is necessary to induce a response in PIK3CA-mutant colorectal cancers. The PI3K/mTORC1/2 inhibitor copanlisib has demonstrated some clinical activity in PIK3CA-mutant solid tumors as part of the NCI-MATCH trial. In this study, we evaluate potential combination therapies that could enhance the efficacy of copanlisib and other similar inhibitors in PIK3CA-mutant colorectal cancers. Using a novel high-throughput drug screen method in Apc- and Pik3ca-mutant mouse-derived cancer organoids, we identify navitoclax, a BCL-2 family inhibitor, as a drug that could potentially enhance the response to copanlisib. Across multiple in vitro and in vivo colorectal cancer models, navitoclax enhanced PI3K/mTOR inhibition (copanlisib, sapanisertib, and dactolisib) and induced apoptosis. Furthermore, we examine these combination therapies across a panel of patient-derived cancer organoids with a range of mutation profiles. These studies indicate that KRAS mutations could confer resistance. Furthermore, we identify BCL-xL as the major BCL-2 family target important for the response to this combination in this setting. This provides a strong rationale for mTORC1/2 and BCL-2 family inhibition as a potential treatment strategy for PIK3CA-mutant colorectal cancers.